List of Excipients in Branded Drug TICAGRELOR

Generic Drugs Containing TICAGRELOR

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	ticagrelor	0378-2214	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	ticagrelor	0378-2214	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	ticagrelor	0378-2214	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Mylan Pharmaceuticals Inc	ticagrelor	0378-2214	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	ticagrelor	0378-2214	FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc	ticagrelor	0378-2214	HYPROMELLOSE

What are the Most Frequently-Used Excipients in TICAGRELOR?

# Of NDCs	Excipient
8	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CALCIUM CARBONATE
2	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
11	CELLULOSE, MICROCRYSTALLINE
21	CROSCARMELLOSE SODIUM
3	CROSPOVIDONE

Ticagrelor Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Ticagrelor is a small-molecule, orally administered P2Y12 platelet inhibitor with substantial formulation opportunity despite mature branded-tablet technology. The commercial focus is shifting from basic immediate-release tablets to differentiated generics, orally disintegrating products, pediatric and dysphagia-friendly presentations, and improved solubility systems. The largest risks are generic price erosion, limited clinical differentiation, and patent disputes over method-of-use or formulation claims.

What is the formulation profile of ticagrelor?

Ticagrelor is a reversible P2Y12 receptor antagonist approved for reducing thrombotic cardiovascular events in acute coronary syndrome and selected patients with a history of myocardial infarction or coronary artery disease. It is marketed primarily as 60 mg and 90 mg immediate-release tablets under the Brilinta brand in the United States and Brilique in several other markets.[1,2]

Ticagrelor has formulation characteristics that create excipient-development opportunities:

Attribute	Formulation implication
Small-molecule active pharmaceutical ingredient	Generic and hybrid-drug pathways are available
Low aqueous solubility	Wetting, particle-size reduction, amorphous dispersion and lipid-based approaches may improve dissolution
Oral immediate-release dosing	Rapid disintegration and reproducible dissolution are commercially important
High clinical value in cardiovascular disease	Dose accuracy and supply reliability are more important than premium aesthetics
Chronic and acute-use indications	Products must support both hospital initiation and long-term outpatient treatment
60 mg and 90 mg strengths	Strength proportionality, content uniformity and tablet-size control affect manufacturing cost
No biologic structure	Biosimilar competition is not relevant

Ticagrelor is generally treated as a low-solubility, high-permeability development candidate. The practical formulation objective is rapid and complete dissolution rather than prolonged release.

What excipients are used in branded Brilinta tablets?

The U.S. prescribing information identifies a conventional direct-compression or compression-based excipient platform. Core tablet ingredients include mannitol, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose and magnesium stearate. The film coating contains hypromellose, titanium dioxide, talc and iron oxide colorants.[1]

Function	Brilinta-type excipient	Development purpose
Diluent and mouthfeel modifier	Mannitol	Bulk, compressibility and relatively clean sensory profile
Mineral diluent	Dibasic calcium phosphate	Tablet mass, hardness and flow
Superdisintegrant	Sodium starch glycolate	Water uptake and rapid tablet breakup
Binder	Hydroxypropyl cellulose	Granule or tablet mechanical strength
Lubricant	Magnesium stearate	Ejection and manufacturing efficiency
Film former	Hypromellose	Surface protection and swallowability
Opacifier	Titanium dioxide	Appearance and light protection
Glidant or coating aid	Talc	Coating performance
Colorants	Iron oxides	Strength identification

The branded composition is commercially useful as a benchmark, but it does not prevent a generic applicant from selecting different excipients. The regulatory requirement is pharmaceutical equivalence and bioequivalence, not excipient identity.

Which excipient platforms are most attractive for ticagrelor?

Immediate-release tablets with conventional excipients

The lowest-risk opportunity is a conventional immediate-release tablet using mannitol or microcrystalline cellulose as the principal diluent, sodium starch glycolate or crospovidone as the disintegrant, hydroxypropyl cellulose or povidone as the binder, and magnesium stearate as the lubricant.

This approach has the shortest development path because:

• The dosage form matches the reference product.
• Standard tablet equipment can be used.
• Excipient safety is well established.
• A comparative dissolution strategy is straightforward.
• The product is suitable for an ANDA if the reference product and jurisdictional requirements are met.

The main technical risk is dissolution sensitivity to lubricant level, compression force, granulation endpoint and API particle size.

Amorphous solid dispersions

Amorphous solid dispersions can increase apparent solubility and reduce dependence on micronized API. Potential polymers include hypromellose acetate succinate, hydroxypropyl methylcellulose, copovidone and polyvinylpyrrolidone.

This platform is most valuable when ticagrelor particle-size reduction does not provide sufficient dissolution robustness. It may permit:

• Smaller tablets
• More rapid dissolution
• Lower sensitivity to API particle-size variation
• Improved performance across pH conditions

The primary barriers are physical stability, polymer hygroscopicity, residual solvent control and scale-up. A solid-dispersion product may also require more extensive stability and process characterization than a conventional generic.

Nanocrystal and micronized-API systems

Particle-size reduction is a practical route for improving dissolution without introducing a large polymer load. Wet milling, high-pressure homogenization or precipitation-based approaches can generate nanocrystals or submicron particles.

Commercial advantages include lower excipient burden and compatibility with immediate-release tablets or suspensions. Risks include agglomeration, crystal-growth during storage, milling-induced polymorphic changes and content-uniformity problems at the 60 mg strength.

Cyclodextrin and inclusion-complex systems

Cyclodextrins can improve apparent solubility and may support liquid formulations or orally disintegrating products. However, the cost of cyclodextrin, dose burden, potential gastrointestinal effects and manufacturing complexity reduce the attractiveness of this approach for a high-volume generic tablet.

Cyclodextrin systems are more commercially relevant for:

• Pediatric oral liquids
• Hospital extemporaneous-use products
• Dysphagia products
• Rapid-dissolution oral films

Lipid-based systems

Self-emulsifying or self-microemulsifying systems may improve exposure where dissolution limits absorption. They are less naturally suited to a conventional low-cost tablet but may support softgels, liquid-filled capsules or specialized oral formulations.

The key risks are food-effect behavior, capsule compatibility, excipient oxidation, dose uniformity and higher packaging cost.

Orally disintegrating and oral-dispersible tablets

An orally disintegrating ticagrelor product could address patients with dysphagia, emergency-use settings and adherence problems. Candidate excipients include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, croscarmellose sodium, copovidone and taste-masking polymers.

Ticagrelor’s bitterness makes taste masking central. Ion-exchange resins, polymer coatings, lipid barriers or flavor systems may be required. The product must disintegrate rapidly without creating an unacceptable bitter aftertaste.

What formulations are protected by ticagrelor patents?

Ticagrelor’s original composition-of-matter protection was based on AstraZeneca patent filings covering triazolotriazine compounds and related pharmaceutical uses. The principal composition protection has expired or reached the end of its effective U.S. term, allowing generic entry under the ANDA framework, subject to applicable listed patents and litigation outcomes.[3,4]

Later protection has focused on:

• Cardiovascular treatment methods
• Duration and intensity of antiplatelet therapy
• Patient-selection criteria
• Combination treatment with aspirin
• Secondary-prevention use after myocardial infarction
• Specific tablet, dosage and manufacturing claims in some jurisdictions

Formulation developers should separate three patent questions:

1. Whether the active ingredient itself remains protected.
2. Whether the proposed indication is covered by an unexpired method-of-use patent.
3. Whether the manufacturing process, particle form or formulation creates independent infringement exposure.

A generic applicant can often use a Section viii statement to carve out patented indications from labeling where U.S. law permits. This is more difficult when the patented use is tightly integrated with the approved label or when a formulation claim covers the product itself.

When does ticagrelor lose exclusivity?

The core commercial exclusivity period has ended in major markets, but generic timing remains jurisdiction-specific.

Milestone	Commercial significance
European authorization of Brilique	Established the original European regulatory franchise
U.S. FDA approval of Brilinta in 2011	Started the U.S. branded market and regulatory exclusivity framework
Loss of core composition protection	Opened the principal pathway for generic development
Later method-of-use protections	Can delay or limit launch for specific indications
ANDA approvals and settlements	Determine actual generic launch timing
Post-launch litigation	Can alter launch dates, product labeling and damages exposure

FDA exclusivity and patent expiry are separate. Regulatory exclusivity may expire before patent protection, and a generic applicant may receive approval while remaining subject to a launch restriction created by settlement or court order. The FDA Orange Book is the controlling source for current U.S. listed patents, use codes and expiration information.[3]

What is the Orange Book status of ticagrelor?

The Orange Book provides the relevant U.S. patent listings for Brilinta and identifies patents that an ANDA applicant must address through a Paragraph IV certification, a paragraph III certification or a Section viii statement.[3]

A ticagrelor applicant should evaluate:

• Listed patents for 60 mg and 90 mg tablets
• Use codes associated with acute coronary syndrome and secondary prevention
• Patent expiry, pediatric extensions and patent-term adjustments
• Whether a listed patent covers the proposed label
• Whether the proposed product uses a different formulation or manufacturing route
• The effect of any Paragraph IV notice and resulting litigation

The Orange Book does not establish that a patent is valid or infringed. It establishes the regulatory patent-listing framework. Courts determine validity, enforceability and infringement.

Which companies are challenging ticagrelor exclusivity?

Competition is expected from generic pharmaceutical companies pursuing abbreviated applications and equivalent oral tablets. The relevant competitive set includes:

• Large multinational generic manufacturers
• Indian and Southeast Asian manufacturers
• Regional cardiovascular-product companies
• Contract development and manufacturing organizations supplying finished-dose products
• Specialty firms developing orally disintegrating or liquid presentations

A Paragraph IV challenge can produce a 30-month FDA approval stay when the statutory conditions are met. The commercial outcome depends on the number of challengers, settlement terms, patent strength and whether the first filer qualifies for 180-day generic exclusivity.[5]

Publicly disclosed settlement terms must be analyzed separately for each defendant. Typical provisions may include an agreed launch date, a license under specified patents, restrictions on authorized-generic competition or no-admission clauses. A settlement can preserve substantial branded revenue even after FDA approval of the generic.

Is there biosimilar risk for ticagrelor?

No. Ticagrelor is a chemically synthesized small molecule, not a biologic. The competitive pathway is generic substitution, not biosimilar interchangeability under the Biologics Price Competition and Innovation Act.

The relevant U.S. pathways are:

• ANDA approval for pharmaceutical equivalence and bioequivalence
• Paragraph IV litigation for listed patents
• Section viii labeling carve-outs for patented uses
• A 505(b)(2) application for materially differentiated formulations or routes

A 505(b)(2) product could target an oral suspension, orally disintegrating tablet or other formulation with clinical or pharmacokinetic differentiation. That pathway generally carries greater development cost than a conventional ANDA.

What commercial opportunities exist for ticagrelor excipients?

Low-cost generic tablets

This is the largest volume opportunity. The winning formulation will usually combine:

• Low-cost, compendial excipients
• Robust tablet compression
• Fast dissolution across pH conditions
• Low friability
• Efficient coating
• Stable supply of mannitol, disintegrant and binder

Manufacturers can compete through cost of goods, packaging, supply reliability and hospital contracting rather than major clinical differentiation.

Premium orally disintegrating products

An orally disintegrating ticagrelor product could command a higher price if it demonstrates improved administration for patients unable to swallow tablets. The commercial case is strongest in emergency departments, post-acute care, geriatrics and patients receiving enteral care.

The development challenge is taste masking. A product that disintegrates quickly but leaves substantial bitterness may have limited adherence value.

Pediatric and liquid formulations

Ticagrelor has limited direct pediatric commercial scale compared with adult cardiovascular use, but an oral liquid could support specialized hospital and congenital-heart-disease applications. Suspending agents, wetting agents, preservatives and flavor systems must be selected for dose uniformity and chemical stability.

Potential excipient classes include:

• Polysorbates or poloxamers for wetting
• Xanthan gum or microcrystalline cellulose-carboxymethylcellulose for suspension control
• Citrate or phosphate buffers for pH management
• Benzoate or sorbate preservatives where justified
• Taste-masking polymers and flavors

Coated particles and sachets

Multiparticulate products may improve flexibility for dysphagia and dose titration. Coated ticagrelor particles can be filled into capsules or sachets, but coating uniformity and dose segregation are major manufacturing risks.

Hospital-use presentations

A rapidly dispersible tablet or reconstitutable suspension could have value in acute coronary syndrome protocols. Commercial adoption would depend on compatibility with hospital formularies, administration speed, storage requirements and evidence that the product does not compromise dosing accuracy.

How strong is the ticagrelor patent estate?

The estate is strongest for the original active-ingredient invention and weaker for ordinary tablet formulations using established excipients. A conventional generic using a different excipient combination generally faces lower formulation-patent exposure than a product that copies a claimed particle form, solid dispersion, coating architecture or specialized dosage form.

Patent category	Relative risk for generic developer
Original compound claims	Low after effective expiry, subject to jurisdiction
Standard immediate-release tablet	Usually low to moderate
Specific solid-state or particle claims	Moderate
Amorphous dispersion claims	Moderate to high if overlapping
Specialized ODT or taste-masked dosage form	Moderate to high
Method-of-use claims	Depends on label and carve-out
Manufacturing-process claims	Depends on process similarity
Pediatric or hospital-use claims	Variable

Freedom-to-operate analysis must cover U.S., Europe, Japan, China, India and major Latin American markets. Patent expiry and enforceability differ by country, and a product cleared for one jurisdiction may require a different label or manufacturing process elsewhere.

What generic launch scenarios exist for ticagrelor?

Scenario 1: Conventional ANDA launch

A manufacturer launches 60 mg and 90 mg tablets after patent resolution or settlement. Price declines are rapid, with hospital and pharmacy purchasing groups driving substitution.

Scenario 2: Authorized-generic competition

The brand owner or a partner supplies an authorized generic. This can reduce the first independent generic’s market share and preserve part of the originator’s volume economics.

Scenario 3: Carved-out-label launch

A generic launches with a label that omits one or more patented indications. The product can compete in non-protected indications but may face pharmacy-substitution and prescriber-education constraints.

Scenario 4: Differentiated formulation launch

A 505(b)(2) or jurisdictionally equivalent product introduces an orally disintegrating tablet, liquid or rapid-dispersing formulation. This can avoid direct price competition but requires clinical, regulatory and commercial investment.

What revenue exposure does ticagrelor create?

Brilinta is a material AstraZeneca cardiovascular product, with global sales reported in the company’s annual filings.[6] Revenue exposure depends on:

• The number of approved generic competitors
• The launch date of the first generic
• Whether an authorized generic is supplied
• The share of sales from 60 mg versus 90 mg tablets
• Hospital versus retail channel mix
• Geographic patent status
• Reimbursement and tender dynamics

The first generic entrant usually captures disproportionate volume, while later entrants compete primarily on price. Excipient suppliers can benefit from multi-source demand for mannitol, superdisintegrants, binders, film-coating systems and taste-masking polymers even when finished-dose prices decline.

Key Takeaways

• Ticagrelor offers a large conventional-generic opportunity and smaller premium opportunities in ODT, liquid and dysphagia-friendly formats.
• The branded tablet uses mannitol, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose and magnesium stearate, with a hypromellose film coat.[1]
• Solubility and dissolution are the main formulation-development targets.
• Amorphous dispersions, nanocrystals and lipid systems may improve performance but increase CMC and stability risk.
• Ticagrelor has no biosimilar pathway because it is a small molecule.
• Orange Book listings, Paragraph IV certifications and method-of-use patents remain central to U.S. launch timing.[3,5]
• Conventional tablets face the greatest price pressure; differentiated dosage forms may support higher margins.
• Patent risk is generally higher for specialized particle, solid-state, taste-masked and method-of-use products than for ordinary generic tablets.
• Excipient suppliers have opportunities in direct-compression systems, superdisintegrants, coating platforms, suspension systems and taste-masking technologies.

FAQs

Can ticagrelor be formulated as an oral suspension?

Yes. An oral suspension is technically feasible, but it requires validated particle-size control, wetting, sedimentation behavior, dose uniformity, preservative strategy and chemical stability.

Which excipient is most important for ticagrelor tablet dissolution?

The superdisintegrant system is critical, but API particle size, lubricant concentration and compression force can have an equally large effect on dissolution performance.

Does changing the excipient composition avoid ticagrelor patent infringement?

Not automatically. A different excipient composition may avoid a narrow formulation claim, but it does not eliminate method-of-use, particle-form, process or product-by-process risks.

Is ticagrelor suitable for an orally disintegrating film?

It may be technically suitable, but the low dose does not eliminate the need for bitterness control. Taste masking, dose uniformity and film mechanical strength are the primary development constraints.

Which excipient suppliers are positioned to benefit from ticagrelor genericization?

Suppliers of mannitol, crospovidone, sodium starch glycolate, croscarmellose sodium, copovidone, film-coating systems, suspension polymers and taste-masking materials are positioned to participate in ticagrelor generic supply chains.

References

1. U.S. Food and Drug Administration. (2024). Brilinta (ticagrelor) tablets: U.S. prescribing information.
2. European Medicines Agency. (2024). Brilique: European public assessment report.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. AstraZeneca. (2024). Annual report 2023.
5. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.
6. AstraZeneca. (2025). Annual report 2024.